A large analysis of more than 2,300 patients from nine major clinical trials has found that race does not affect how well CAR T-cell therapy works for people with B-cell lymphoma. Instead, patient outcomes depend mainly on clinical factors such as overall health and how advanced the disease is at the start of treatment. When […]
The Phase 3 Neo-Healer trial has met its main goal, showing that a new treatment combination can improve outcomes for patients with HER2-positive breast cancer. The study found that anbenitamab (KN026) combined with albumin-bound docetaxel led to a significantly higher rate of total pathologic complete response compared with the current standard treatment using trastuzumab, pertuzumab,
Researchers have developed an AI-powered tool called PhenopyCell that can predict how patients with extensive-stage Small Cell Lung Cancer will respond to platinum-based chemotherapy before treatment begins. This is important because about 70% of patients are diagnosed at an advanced stage, and doctors currently lack reliable biomarkers to guide treatment decisions. The tool works by
AI Tool Predicts Chemotherapy Response in Advanced Small Cell Lung Cancer Read More »
Colorectal cancer is becoming a growing crisis, especially among younger adults. It is now a leading cause of cancer death in people under 50, with cases rising about 3% each year in those aged 20 to 49, even as rates fall in older adults. Many younger patients are diagnosed late, with nearly 75% already at
Rising Colorectal Cancer in Young Adults Signals Urgent Clinical Challenge Read More »
The U.S. Food and Drug Administration reported major oncology updates in March 2026, highlighting advances in precision treatment and imaging. For advanced Hodgkin lymphoma, Nivolumab plus AVD is now approved as first-line therapy, improving outcomes over older regimens. In ovarian cancer, Relacorilant with chemotherapy was approved for platinum-resistant disease, cutting the risk of death by
FDA Advances Precision Oncology with New Approvals and Accelerated Reviews in March 2026 Read More »
Multiple myeloma treatment is shifting toward precision medicine, where care is tailored to each individual patient instead of broad risk groups. A new artificial intelligence tool called CORAL-histomorph can analyze standard bone marrow biopsy images and predict key genetic abnormalities—such as the 11;14 translocation—with over 90% accuracy. This is significant because it removes the need
AI Tool Advances Precision Medicine in Multiple Myeloma Read More »
UK researchers have mapped the full range of mutations across 16 cancer types in a study published in Nature Genetics. Part of Genomics England’s 100,000 Genomes Project, the research analyzed the whole genomes of nearly 11,000 NHS patients, identifying 134 mutational signatures—genetic “fingerprints” left by DNA damage, including 26 previously unknown. Beyond single-letter DNA changes,
UK Study Maps 134 Cancer Mutation Signatures, Expanding Precision Medicine Opportunities Read More »
The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to WU-CART-007, an off-the-shelf CAR-T therapy for aggressive T-cell blood cancers. Developed at Washington University School of Medicine and licensed to Wugen, the therapy targets T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Early clinical data show a 91% overall response rate, with nearly
FDA Grants Breakthrough Therapy Designation to WU-CART-007 for Aggressive T-Cell Cancers Read More »
A recent study reveals that the microRNA miR-362-3p acts as a powerful tumor suppressor in gastric cancer. Researchers found that high levels of miR-362-3p slow cancer cell growth, reduce migration, and prevent the epithelial-mesenchymal transition, which allows tumors to become more invasive. The study showed that miR-362-3p directly targets DEP-1, a protein that promotes tumor
MicroRNA miR-362-3p Identified as Key Tumor Suppressor in Gastric Cancer Read More »
A recent study uncovers a new mechanism by which colorectal cancer (CRC) evades the immune system and resists PD-L1 blockade. Researchers found that the protein G3BP2 undergoes acetylation at lysine 76 (K76), a modification added by the acetyltransferase p300 and removed by the deacetylase HDAC6. This acetylation stabilizes PD-L1 mRNA through interaction with PABPC1, increasing PD-L1